MENLO PARK, Calif., Sept. 15, 2025 /PRNewswire/ -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced ...
Forbes contributors publish independent expert analyses and insights. William A. Haseltine, Ph.D., covers genomics and regenerative medicine Non-invasive prenatal testing, or NIPT, now shapes critical ...
WHEN NON-INVASIVE prenatal testing (NIPT) arrived in 2011, it transformed pregnancy. With a simple blood test, scientists could now sweep a mother’s bloodstream for scraps of placental DNA, uncovering ...
Dec 1 (Reuters) - Wall Street analysts, who acted as lead underwriters for BillionToOne's Nasdaq debut last month, began coverage of the diagnostics firm on Monday with broadly upbeat views, pointing ...
BillionToOne leverages groundbreaking molecular diagnostics technology, targeting massive prenatal and oncology testing markets with rapid revenue growth. Revenues more than doubled to $152 million in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback